CBS 2019
CBSMD教育中心
中 文

动脉粥样硬化性心血管疾病预防

Abstract

Recommended Article

Association of Statin Use With All-Cause and Cardiovascular Mortality in US Veterans 75 Years and Older Antithrombotic Therapy for Atherosclerotic Cardiovascular Disease Risk Mitigation in Patients With Coronary Artery Disease and Diabetes Mellitus The Use of Sex-Specific Factors in the Assessment of Women’s Cardiovascular Risk Simple Electrocardiographic Measures Improve Sudden Arrhythmic Death Prediction in Coronary Disease From Focal Lipid Storage to Systemic Inflammation From Detecting the Vulnerable Plaque to Managing the Vulnerable Patient Coronary calcification in the diagnosis of coronary artery disease Lipid-Modifying Agents, From Statins to PCSK9 Inhibitors: JACC Focus Seminar

Guideline31 August 2019

JOURNAL:Eur Heart J. Article Link

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)

F Mach, C Baigent, ESC Scientific Document Group et al. Keywords: Guidelines; dyslipidaemias; cholesterol; triglycerides; low-density lipoproteins; high-density lipoproteins; apolipoprotein B; lipoprotein(a); lipoprotein remnants; total cardiovascular risk; treatment (lifestyle); treatment (drugs); treatment (adherence); very low-density lipoproteins; familial hypercholesterolaemia

FULL TEXT PDF